Thieler Law Corp advises investors with losses exceeding $100,000 of the January 22, 2016 lead plaintiff deadline in a class action lawsuit filed against Osiris Therapeutics Inc (NASDAQ: OSIR) (“Osiris Therapeutics” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Osiris Therapeutics securities between May 12, 2014 and November 20, 2015, have until January 22, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Osiris Therapeutics securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com .  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Osiris Therapeutics Inc improperly recognized revenue under contracts it had with its distributors and the Company's disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015. As a result, Osiris Therapeutics Inc public statements were materially false and misleading at all relevant times.

On November 16, 2015, Osiris Therapeutics Inc announced that it has "determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014." Osiris Therapeutics Inc missed its revenue goal in three of the last four quarters.

After the release of this news, the Company's shares fell to as low as $9.80 per share on November 17, 2015.

If you were negatively impacted by your investment in Osiris Therapeutics securities between May 12, 2014 and November 20, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185